Is early-onset colorectal cancer an evolving pandemic? Real-world data from a tertiary cancer center

Early onset Colorectal Cancer (EOCRC), defined as those diagnosed under the age of 50, has been increasing rapidly since 1970. UK data on EOCRC are currently limited and better understanding of the condition is needed. A single-center retrospective study of patients with EOCRC treated over 9 years (...

Full description

Saved in:
Bibliographic Details
Published in:The oncologist (Dayton, Ohio) Ohio), 2024-10, Vol.29 (12), p.e1680-e1691
Main Authors: Angelakas, Angelos, Christodoulou, Thekla, Kamposioras, Konstantinos, Barriuso, Jorge, Braun, Michael, Hasan, Jurjees, Marti, Kalena, Misra, Vivek, Mullamitha, Saifee, Saunders, Mark, Cook, Natalie
Format: Article
Language:English
Subjects:
Adult
Age of Onset
Colorectal Neoplasms - epidemiology
Colorectal Neoplasms - mortality
Colorectal Neoplasms - pathology
Colorectal Neoplasms - therapy
Female
Gastrointestinal Cancer
Humans
Male
Middle Aged
Pandemics
Retrospective Studies
Tertiary Care Centers - statistics & numerical data
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Early onset Colorectal Cancer (EOCRC), defined as those diagnosed under the age of 50, has been increasing rapidly since 1970. UK data on EOCRC are currently limited and better understanding of the condition is needed. A single-center retrospective study of patients with EOCRC treated over 9 years (2013-2021) at a large UK cancer center was performed. Clinicopathological features, risk factors, molecular drivers, treatment, and survival were analyzed. In total, 203 patients were included. A significant increase in cases was reported from 2018-2019 (n = 33) to 2020-2021 (n = 118). Sporadic EOCRC accounted for 70% of cases and left-sided tumors represented 70.9% (n = 144). Median duration of symptoms was 3 months, while 52.7% of the patients had de-novo metastatic disease. Progression-free survival after first-line chemotherapy was 6 months (95% CI, 4.85-7.15) and median overall survival (OS) was 38 months (95% CI, 32.86-43.14). In the advanced setting, left-sided primary tumors were associated with a median OS benefit of 14 months over right-sided primaries (28 vs 14 months, P = .009). Finally, primary tumor resection was associated with median OS benefit of 21 months compared with in situ tumors (38 vs 17 months, P 
ISSN:1083-7159
1549-490X
1549-490X
DOI:10.1093/oncolo/oyae239